  13C-Metabolic Flux Analysis (13C-MFA) and Flux Balance Analysis (FBA) are
widely used to investigate the operation of biochemical networks in both
biological and biotechnological research. Both of these methods use metabolic
reaction network models of metabolism operating at steady state, so that
reaction rates (fluxes) and the levels of metabolic intermediates are
constrained to be invariant. They provide estimated (MFA) or predicted (FBA)
values of the fluxes through the network in vivo, which cannot be measured
directly. A number of approaches have been taken to test the reliability of
estimates and predictions from constraint-based methods and to decide on and/or
discriminate between alternative model architectures. Despite advances in other
areas of the statistical evaluation of metabolic models, validation and model
selection methods have been underappreciated and underexplored. We review the
history and state-of-the-art in constraint-based metabolic model validation and
model selection. Applications and limitations of the X2-test of
goodness-of-fit, the most widely used quantitative validation and selection
approach in 13C-MFA, are discussed, and complementary and alternative forms of
validation and selection are proposed. A combined model validation and
selection framework for 13C-MFA incorporating metabolite pool size information
that leverages new developments in the field is presented and advocated for.
Finally, we discuss how the adoption of robust validation and selection
procedures can enhance confidence in constraint-based modeling as a whole and
ultimately facilitate more widespread use of FBA in biotechnology in
particular.
